Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Natera (NTRA)
NASDAQ:NTRA
NTRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$68.03 - $183.00
Previous CloseN/A
Volume352.74K
Average Volume (3M)1.34M
Market Cap
$22.89B
Enterprise Value$15.27B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Feb 26, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding132,020,810
10 Day Avg. Volume1,198,993
30 Day Avg. Volume1,340,233
Standard Deviation0.16
R-Squared0.28
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.94
Price to Cash Flow (P/CF)110.50
P/FCF Ratio147.90
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit30.98
Enterprise Value/Ebitda-93.82
Forecast
1Y Price Target
$194.50Price Target Upside12.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNatera preannounced a strong top-line revenue beat of $472M, significantly above expectations.
Market Reach And AdoptionNatera's data readouts, especially the '702 study results, can support broader clinician acceptance and guideline inclusion for Signatera, potentially boosting its market reach.
Reimbursement And Financial SupportA large national payor has begun to reimburse Natera's RhD test, indicating progress in gaining financial support for the test.
Bears Say
Clinical Trial ExpectationsALTAIR fell in line to already lowered expectations with the study not showing statistically significant DFS in all patients.
Market CompetitionWith these MRD launches, NTRA addresses any competitive risk from whole genome sequencing (WGS), higher sensitivity and tissue-naive assays, while its catalyst path ahead should only help drive the momentum in NTRA shares higher.
Reimbursement ChallengesMedicare FFS provides a disproportionate amount of Signatera revenue due to a significant portion of volumes not being reimbursed by other sources.
---
Ownership Overview
5.05% Insiders
26.28% Mutual Funds
32.59% Other Institutional Investors
21.49% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NTRA FAQ
What was Natera’s price range in the past 12 months?
Natera lowest stock price was $68.03 and its highest was $183.00 in the past 12 months.
What is Natera’s market cap?
Natera’s market cap is $22.89B.
When is Natera’s upcoming earnings report date?
Natera’s upcoming earnings report date is Feb 26, 2025 which is in 7 days.
How were Natera’s earnings last quarter?
Natera released its earnings results on Nov 12, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.575 by $0.315.
Is Natera overvalued?
According to Wall Street analysts Natera’s price is currently Undervalued.
Does Natera pay dividends?
Natera does not currently pay dividends.
What is Natera’s EPS estimate?
Natera’s EPS estimate is -0.38.
How many shares outstanding does Natera have?
Natera has 132,020,810 shares outstanding.
What happened to Natera’s price movement after its last earnings report?
Natera reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.575. Following the earnings report the stock price went up 19.131%.
Which hedge fund is a major shareholder of Natera?
Currently, no hedge funds are holding shares in NTRA
---
Natera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$194.50 (12.17% Upside)
$194.50 (12.17% Upside)
Blogger Sentiment
Bullish
NTRA Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 202.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.87%
12-Months-Change
Fundamentals
Return on Equity
-25.82%
Trailing 12-Months
Asset Growth
9.98%
Trailing 12-Months
Company Description
Natera
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.
---
NTRA Company Deck
---
NTRA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Natera's strong financial and operational performance, with record revenue growth, increased oncology test volumes, and significant clinical data achievements. While there were some challenges related to weather impacts and litigation expenses, the overall outlook remains positive with raised guidance and strong cash flow generation.Read More>---
NTRA Stock 12 Month Forecast
Average Price Target
$194.50
▲(12.17% Upside)
Technical Analysis
Best Analysts Covering NTRA
1 Year
1 Year Success Rate
15/15 ratings generated profit
1 Year Average Return
+80.90%
reiterated a buy rating 22 days ago
Copying Matthew Sykes's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +80.90% per trade.
---